TY - JOUR
T1 - COVAD survey 2 long-term outcomes
T2 - unmet need and protocol
AU - COVAD Study Group
AU - Fazal, Zoha Zahid
AU - Sen, Parikshit
AU - Joshi, Mrudula
AU - Ravichandran, Naveen
AU - Lilleker, James B.
AU - Agarwal, Vishwesh
AU - Kardes, Sinan
AU - Kim, Minchul
AU - Day, Jessica
AU - Makol, Ashima
AU - Milchert, Marcin
AU - Gheita, Tamer
AU - Salim, Babur
AU - Velikova, Tsvetelina
AU - Gracia-Ramos, Abraham Edgar
AU - Parodis, Ioannis
AU - Nikiphorou, Elena
AU - Tan, Ai Lyn
AU - Chatterjee, Tulika
AU - Cavagna, Lorenzo
AU - Saavedra, Miguel A.
AU - Shinjo, Samuel Katsuyuki
AU - Ziade, Nelly
AU - Selva-O’Callaghan, Albert
AU - Nune, Arvind
AU - Knitza, Johannes
AU - Kuwana, Masataka
AU - Gutiérrez, Carlos Enrique Toro
AU - Caballero-Uribe, Carlo Vinicio
AU - Dey, Dzifa
AU - Distler, Oliver
AU - Chinoy, Hector
AU - Agarwal, Vikas
AU - Aggarwal, Rohit
AU - Gupta, Latika
AU - Barman, Bhupen
AU - Singh, Yogesh Preet
AU - Ranjan, Rajiv
AU - Jain, Avinash
AU - Pandya, Sapan C.
AU - Pilania, Rakesh Kumar
AU - Sharma, Aman
AU - M, Manesh Manoj
AU - Gupta, Vikas
AU - Kavadichanda, Chengappa G.
AU - Patro, Pradeepta Sekhar
AU - Ajmani, Sajal
AU - Phatak, Sanat
AU - Goswami, Rudra Prosad
AU - Chowdhury, Abhra Chandra
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Vaccine hesitancy is considered a major barrier to achieving herd immunity against COVID-19. While multiple alternative and synergistic approaches including heterologous vaccination, booster doses, and antiviral drugs have been developed, equitable vaccine uptake remains the foremost strategy to manage pandemic. Although none of the currently approved vaccines are live-attenuated, several reports of disease flares, waning protection, and acute-onset syndromes have emerged as short-term adverse events after vaccination. Hence, scientific literature falls short when discussing potential long-term effects in vulnerable cohorts. The COVAD-2 survey follows on from the baseline COVAD-1 survey with the aim to collect patient-reported data on the long-term safety and tolerability of COVID-19 vaccines in immune modulation. The e-survey has been extensively pilot-tested and validated with translations into multiple languages. Anticipated results will help improve vaccination efforts and reduce the imminent risks of COVID-19 infection, especially in understudied vulnerable groups.
AB - Vaccine hesitancy is considered a major barrier to achieving herd immunity against COVID-19. While multiple alternative and synergistic approaches including heterologous vaccination, booster doses, and antiviral drugs have been developed, equitable vaccine uptake remains the foremost strategy to manage pandemic. Although none of the currently approved vaccines are live-attenuated, several reports of disease flares, waning protection, and acute-onset syndromes have emerged as short-term adverse events after vaccination. Hence, scientific literature falls short when discussing potential long-term effects in vulnerable cohorts. The COVAD-2 survey follows on from the baseline COVAD-1 survey with the aim to collect patient-reported data on the long-term safety and tolerability of COVID-19 vaccines in immune modulation. The e-survey has been extensively pilot-tested and validated with translations into multiple languages. Anticipated results will help improve vaccination efforts and reduce the imminent risks of COVID-19 infection, especially in understudied vulnerable groups.
KW - Autoimmune diseases
KW - COVID-19
KW - Long-term adverse effects
KW - Registries
KW - Vaccination
UR - https://www.scopus.com/pages/publications/85139571711
U2 - 10.1007/s00296-022-05157-6
DO - 10.1007/s00296-022-05157-6
M3 - Article
C2 - 35964271
AN - SCOPUS:85139571711
SN - 0172-8172
VL - 42
SP - 2151
EP - 2158
JO - Rheumatology International
JF - Rheumatology International
IS - 12
ER -
SDG 3 Good Health and Well-being